Sanofi-Aventis S.A. ADR (SNY)

$43.18 -0.82 (-1.86%)
Market Cap 105.46B
Revenue (ttm) 52.85B
Net Income (ttm) 8.84B
EPS (ttm) N/A
PE Ratio 9.56
Forward PE 8.90
Profit Margin 16.72%
Debt to Equity Ratio 0.25
Volume 2,245,200
Avg Vol 3,285,868
Day's Range N/A - N/A
Shares Out 2.42B
Stochastic %K 95%
Beta 0.34
Analysts Sell
Price Target $53.39

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscienti...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 33 1 53 77 40 00
Address:
46, avenue de la Grande ArmEe, Paris, France
Dilly_Due
Dilly_Due Jul. 14 at 4:12 PM
$VXRT I don't agree that these votes sabotage anything as they don't have teeth yet. Plurality still applies right? But this vote could raise eyebrows in more important places such as the large activist investors, potential new suitors to fight an $SNY take under, who knows, maybe even a couple Attorneys General. Personally I hope 300 million votes are cast to WITHHOLD and it raises questions that only a share count would have determined. I don't know if that is possible but I would love it. Just my humble opinion. Do your own DD.
1 · Reply
MQuick
MQuick Jul. 14 at 2:08 PM
$GANX its time $SNY
0 · Reply
ZacksResearch
ZacksResearch Jul. 14 at 1:55 PM
💰 How $NVAX is quietly building a high-margin royalty business beyond COVID vaccines Novavax's proprietary Matrix-M adjuvant is gaining traction as more vaccine makers look to enhance immune responses without developing their own platform. Key developments: • $SNY received a license to use Matrix-M in additional vaccines, with Novavax eligible for up to $210M in milestones plus royalties • $PFE secured rights to Matrix-M in up to two disease areas under a deal worth up to $530M • Multiple partners are now evaluating Matrix-M across infectious disease and oncology programs • Future licensing deals could generate recurring revenue through upfront payments, milestones, royalties and supply agreements See the upside Wall Street expects for $NVAX. 👇 https://www.zacks.com/stock/research/NVAX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38772&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38772
1 · Reply
Makingmillions192
Makingmillions192 Jul. 14 at 1:51 PM
$MRK $SNY $VKTX While Big Pharma races to acquire oral GLP-1 delivery tech, this platform developer is about to drop human and next-gen animal datasets that could rewrite the market's tolerability standards. The Late-Summer Data Drop Schedule: Lexaria Bioscience ($LEXX) Mid-August 2026 | Animal Study #2 (GLP-1-A26-2) Pharma is watching platform compatibility and PK data for tomorrow's next-gen blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. Late August / Early September 2026 | Human Study #7 (GLP-1-H26-7) THE MAIN EVENT. Head-to-head 5-week steady-state human data comparing DehydraTECH-semaglutide tablets directly against Wegovy. Pharma is tracking bio-absorption and a projected ~40% reduction in GI side effects. Early September 2026 | Animal Study #1 (GLP-1-A26-1) Pharma is watching alternative novel formulations designed to bypass or improve upon traditional, erratic SNAC-inclusive carriers.
0 · Reply
grampslol
grampslol Jul. 13 at 4:24 PM
$MNKD furosemide drug won't be able to compete with furosemide products from $PFE $LLY $SNY amgen and countless other big pharma ... if approved furoscix will be afizzle part 2 ... lol #pumperslie #dilutionsthesolution
0 · Reply
Estimize
Estimize Jul. 13 at 10:09 AM
Wall St is expecting 1.10 EPS for $SNY Q2 [Reporting 07/30 BMO] http://www.estimize.com/intro/sny?chart=historical&metric_name=eps&utm_cont
0 · Reply
p3akyblinder
p3akyblinder Jul. 13 at 12:12 AM
$MLTX It’s very clear that the SLS crowd lacks biotech/investing literacy… hope it works out for them but they’re likely in for a rude awakening. $MRK $ABBV $LLY $SNY will all be MoonLake suitors soon imho GLTA
4 · Reply
Merlintrader
Merlintrader Jul. 12 at 10:57 PM
$SNY Sanofi, Guardant Health $GH and Pharvaris $PHVS - Biotech Radar July 13: catalysts, recent news and key risks https://www.merlintrader.com/biotech-radar-july13-2026/
0 · Reply
IM11
IM11 Jul. 10 at 7:21 PM
$GPCR corporate has been abnormally quiet the past 1 month. No Press Releases since the ADA, no management appearances that I am aware of. Seems like Sanofi's new CEO $SNY has also been pretty quiet other than hiring a new Medical Officer. Seem like maybe a buyout announcement between the two is coming? maybe Monday?
0 · Reply
SGL_FGHI
SGL_FGHI Jul. 10 at 3:18 PM
$TGTX $SNY $BMY $BIIB What’s beautiful about this for a forward-thinking Big Pharma is that TGTX can seamlessly be plugged into their existing neurology sales networks. The winning BP can immediately capture a $4B+ market cap potential without spending years scaling up a brand-new commercial pharmacy infrastructure. For example, because MG is treated by the exact same community neurologists who prescribe MS medications, a Big Pharma acquirer would need zero extra sales infrastructure to cross-sell Briumvi for this indication. The $140.00 per share threshold assumes competitive bidding. This is probably why the buyout will occur SUDDENLY. Personally, I doubt the winning BP will wait until the “de-risked” Phase 3 SUBQ results are reported (expected Q4 2026 / Q1 2027). I expect the winning proposal will be structured with upfront cash and CVR paid out if Briumvi successfully hits its phase 3 endpoint in Myasthenia Gravis OR Schizophrenia.
0 · Reply
Latest News on SNY
Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma

2026-07-10T15:00:52.000Z - 4 days ago

Sanofi (SNY) Secures FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma

Sanofi (SNY) Receives FDA Approval for Subcutaneous Sarclisa Escena

2026-07-10T14:26:33.000Z - 4 days ago

Sanofi (SNY) Receives FDA Approval for Subcutaneous Sarclisa Escena

Sanofi Says FDA Approves Sarclisa Escena SC As First Anticancer Treatment Via On-body Injector

2026-07-10T13:33:13.000Z - 4 days ago

Sanofi Says FDA Approves Sarclisa Escena SC As First Anticancer Treatment Via On-body Injector

Sanofi announces subcutaneous Sarclisa Escena approved in U.S.

2026-07-10T12:45:28.000Z - 4 days ago

Sanofi announces subcutaneous Sarclisa Escena approved in U.S.

Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

Fri, 10 Jul 2026 08:35:00 -0400 - 4 days ago

Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

US FDA approves Sanofi's wearable injector form of blood cancer drug

Fri, 10 Jul 2026 08:22:07 -0400 - 4 days ago

US FDA approves Sanofi's wearable injector form of blood cancer drug

Sanofi price target lowered to $49 from $52 at Morgan Stanley

2026-07-08T11:30:49.000Z - 6 days ago

Sanofi price target lowered to $49 from $52 at Morgan Stanley

EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour

Wed, 08 Jul 2026 06:00:54 -0400 - 6 days ago

EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour

Sanofi SA (SNY) Shares Surge 3.7% -- What GF Score of 68 Tells Investors

2026-07-02T22:53:11.000Z - 12 days ago

Sanofi SA (SNY) Shares Surge 3.7% -- What GF Score of 68 Tells Investors

Sanofi: Availability of the aide-mémoire for Q2 2026 results

2026-07-01T05:34:00.000Z - 13 days ago

Sanofi: Availability of the aide-mémoire for Q2 2026 results

Press Release: Availability of the aide-mémoire for Q2 2026 results

Jul 1, 2026, 1:30 AM EDT - 13 days ago

Press Release: Availability of the aide-mémoire for Q2 2026 results

SNY

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

Tue, 30 Jun 2026 15:04:19 -0400 - 14 days ago

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

Sanofi's Nexviazyme Achieves Key Endpoints In Infantile-Onset Pompe Disease Phase 3 Study

2026-06-30T07:52:59.000Z - 14 days ago

Sanofi's Nexviazyme Achieves Key Endpoints In Infantile-Onset Pompe Disease Phase 3 Study

Sanofi (SNY) Reports Positive Phase 3 Results for Nexviazyme in Pompe Disease

2026-06-30T06:58:10.000Z - 14 days ago

Sanofi (SNY) Reports Positive Phase 3 Results for Nexviazyme in Pompe Disease

Sanofi's Nexviazyme Meets Main Goal In Phase 3 Baby-COMET Study

2026-06-30T06:00:00.000Z - 14 days ago

Sanofi's Nexviazyme Meets Main Goal In Phase 3 Baby-COMET Study

Sanofi: Sanofi's Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

2026-06-30T05:10:00.000Z - 14 days ago

Sanofi: Sanofi's Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 18 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE JNJ LLY MRNA SNY

Sanofi Faces EU Probe With Fines Possibly Reaching 10%

2026-06-26T12:53:24.000Z - 18 days ago

Sanofi Faces EU Probe With Fines Possibly Reaching 10%

Sanofi (SNY) Faces EU Antitrust Investigation Over Vaccine Marketing Practices

2026-06-26T11:57:33.000Z - 18 days ago

Sanofi (SNY) Faces EU Antitrust Investigation Over Vaccine Marketing Practices

EU Commission opens antitrust probe into Sanofi's flu vaccine campaign

Jun 26, 2026, 5:46 AM EDT - 18 days ago

EU Commission opens antitrust probe into Sanofi's flu vaccine campaign

SNY

Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?

2026-06-25T15:11:43.000Z - 19 days ago

Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?

Sanofi: Sanofi Foundation opens new chapter centered on future generations

2026-06-25T06:10:00.000Z - 19 days ago

Sanofi: Sanofi Foundation opens new chapter centered on future generations

Press Release: Sanofi Foundation opens new chapter centered on future generations

Jun 25, 2026, 2:00 AM EDT - 19 days ago

Press Release: Sanofi Foundation opens new chapter centered on future generations

SNY

MacroGenics To Receive $24.5 Mln Milestone Payment From Sanofi For Recent TZIELD Approval

2026-06-23T10:32:25.000Z - 21 days ago

MacroGenics To Receive $24.5 Mln Milestone Payment From Sanofi For Recent TZIELD Approval

Sanofi Wins EU Approval For Cenrifki As First Disability-Targeting Therapy For SPMS Without Relapses

2026-06-23T10:15:09.000Z - 21 days ago

Sanofi Wins EU Approval For Cenrifki As First Disability-Targeting Therapy For SPMS Without Relapses

Sanofi Receives Marketing Rights For Wayrilz In Immune Thrombocytopenia From Japan's MHLW

2026-06-23T09:07:51.000Z - 21 days ago

Sanofi Receives Marketing Rights For Wayrilz In Immune Thrombocytopenia From Japan's MHLW

EU Approves Sanofi's Cenrifki For Non-Relapsing Secondary Progressive Multiple Sclerosis

2026-06-23T06:12:00.000Z - 21 days ago

EU Approves Sanofi's Cenrifki For Non-Relapsing Secondary Progressive Multiple Sclerosis

Sanofi Multiple Sclerosis Drug Gets EU Approval

Jun 23, 2026, 1:37 AM EDT - 21 days ago

Sanofi Multiple Sclerosis Drug Gets EU Approval

SNY

Sanofi: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

2026-06-23T05:22:00.000Z - 21 days ago

Sanofi: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

Jun 23, 2026, 1:15 AM EDT - 21 days ago

Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

ITP SNY

Sanofi: Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

2026-06-23T05:10:00.000Z - 21 days ago

Sanofi: Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

The Department of Health - Abu Dhabi: DoH and Sanofi Partner to Advance Vaccine Innovation

2026-06-22T23:36:00.000Z - 22 days ago

The Department of Health - Abu Dhabi: DoH and Sanofi Partner to Advance Vaccine Innovation

Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics

2026-06-22T22:26:39.000Z - 22 days ago

Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics

MacroGenics, Inc.: MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval

2026-06-22T20:48:00.000Z - 22 days ago

MacroGenics, Inc.: MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval

MacroGenics to receive $24.5M milestone payment from Sanofi

2026-06-22T20:45:10.000Z - 22 days ago

MacroGenics to receive $24.5M milestone payment from Sanofi

MGNX SNY

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval

2026-06-22T20:43:00.000Z - 22 days ago

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval

Sanofi (SNY) Appoints New R&D Chief Amidst Mixed Expectations

2026-06-22T14:56:56.000Z - 22 days ago

Sanofi (SNY) Appoints New R&D Chief Amidst Mixed Expectations

Sanofi appoints Paulo Fontoura as Global Head of R&D

2026-06-22T13:30:14.000Z - 22 days ago

Sanofi appoints Paulo Fontoura as Global Head of R&D

SNY

Sanofi investors likely to view new R&D head as a positive, says BofA

2026-06-22T13:26:54.000Z - 22 days ago

Sanofi investors likely to view new R&D head as a positive, says BofA

SNY

Japan's MHLW Approves Sanofi's Subcutaneous Sarclisa For Multiple Myeloma

2026-06-22T09:43:55.000Z - 22 days ago

Japan's MHLW Approves Sanofi's Subcutaneous Sarclisa For Multiple Myeloma

Sanofi: Sanofi appoints Paulo Fontoura as Global Head of R&D

2026-06-22T06:10:00.000Z - 22 days ago

Sanofi: Sanofi appoints Paulo Fontoura as Global Head of R&D

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Jun 22, 2026, 2:00 AM EDT - 22 days ago

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

SNY

Sanofi's Sarclisa Subcutaneous Combination Therapy Gets Japan Approval For Multiple Myeloma

2026-06-19T12:02:51.000Z - 25 days ago

Sanofi's Sarclisa Subcutaneous Combination Therapy Gets Japan Approval For Multiple Myeloma

Sanofi: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

2026-06-19T10:46:00.000Z - 25 days ago

Sanofi: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Jun 19, 2026, 6:31 AM EDT - 25 days ago

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

SNY

Sanofi SA (SNY) Stock Down 3.5% -- Now Undervalued? GF Score: 73/100

2026-06-17T22:34:09.000Z - 27 days ago

Sanofi SA (SNY) Stock Down 3.5% -- Now Undervalued? GF Score: 73/100

Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank

2026-06-15T16:16:28.000Z - 4 weeks ago

Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank

SNY

Sanofi: Information concerning the total number of voting rights and shares – May 2026

Jun 15, 2026, 12:05 PM EDT - 4 weeks ago

Sanofi: Information concerning the total number of voting rights and shares – May 2026

SNY

Sanofi (SNY) Gains FDA Approval for Expanded Use of Tzield in Type 1 Diabetes

2026-06-13T15:55:51.000Z - 4 weeks ago

Sanofi (SNY) Gains FDA Approval for Expanded Use of Tzield in Type 1 Diabetes

FDA Grants Accelerated Approval To Sanofi's Tzield For Children With Stage 3 Type 1 Diabetes

2026-06-13T06:01:25.000Z - 4 weeks ago

FDA Grants Accelerated Approval To Sanofi's Tzield For Children With Stage 3 Type 1 Diabetes

FDA approves Sanofi's drug for stage 3 type 1 diabetes in children

Jun 12, 2026, 5:19 PM EDT - 4 weeks ago

FDA approves Sanofi's drug for stage 3 type 1 diabetes in children

Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026

Jun 12, 2026, 8:22 AM EDT - 4 weeks ago

Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026

Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright

2026-06-10T13:40:33.000Z - 4 weeks ago

Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright

DNTH

Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus

2026-06-10T11:42:17.000Z - 4 weeks ago

Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus

DNTH

Dianthus sinks after Sanofi halts CIDP Phase 3 study

2026-06-10T11:33:17.000Z - 4 weeks ago

Dianthus sinks after Sanofi halts CIDP Phase 3 study

DNTH

Sanofi to halt riliprubart Mobilize phase 3 study

2026-06-10T10:17:00.000Z - 4 weeks ago

Sanofi to halt riliprubart Mobilize phase 3 study

Sanofi ends Phase 3 riliprubart trial after weak interim results

Jun 10, 2026, 2:38 AM EDT - 4 weeks ago

Sanofi ends Phase 3 riliprubart trial after weak interim results

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

Jun 10, 2026, 2:28 AM EDT - 4 weeks ago

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Jun 10, 2026, 1:00 AM EDT - 4 weeks ago

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Jun 5, 2026, 7:00 AM EDT - 5 weeks ago

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Press Release: Sanofi launches 2026 global employee stock purchase plan

Jun 4, 2026, 4:07 AM EDT - 5 weeks ago

Press Release: Sanofi launches 2026 global employee stock purchase plan

Sanofi Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 5 weeks ago

Sanofi Transcript: Jefferies Global Healthcare Conference 2026

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

May 28, 2026, 1:00 AM EDT - 6 weeks ago

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi: Information concerning the total number of voting rights and shares - April 2026

May 19, 2026, 12:37 PM EDT - 2 months ago

Sanofi: Information concerning the total number of voting rights and shares - April 2026

Sanofi says rare lung disease drug outperforms standard care in trial

May 18, 2026, 3:36 PM EDT - 2 months ago

Sanofi says rare lung disease drug outperforms standard care in trial

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

May 18, 2026, 3:30 PM EDT - 2 months ago

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

May 6, 2026, 2:38 PM EDT - 2 months ago

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

May 6, 2026, 12:42 PM EDT - 2 months ago

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Apr 29, 2026, 12:00 PM EDT - 2 months ago

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Press Release: Sanofi successfully prices 2.3 billion of bond issue

Apr 24, 2026, 2:30 PM EDT - 2 months ago

Press Release: Sanofi successfully prices 2.3 billion of bond issue

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Apr 24, 2026, 6:09 AM EDT - 2 months ago

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Sanofi Earnings Call Transcript: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Sanofi Earnings Call Transcript: Q1 2026

Sanofi Slides: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Sanofi Slides: Q1 2026

Sanofi Earnings release: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Sanofi Earnings release: Q1 2026

Sanofi Posts Higher Sales Amid Leadership Transition

Apr 23, 2026, 2:08 AM EDT - 2 months ago

Sanofi Posts Higher Sales Amid Leadership Transition

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Apr 23, 2026, 1:35 AM EDT - 2 months ago

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Apr 22, 2026, 5:30 PM EDT - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

REGN

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Apr 22, 2026, 1:05 AM EDT - 2 months ago

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Apr 22, 2026, 1:00 AM EDT - 2 months ago

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Apr 13, 2026, 1:00 AM EDT - 3 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

REGN

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Apr 7, 2026, 1:00 AM EDT - 3 months ago

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Mar 31, 2026, 1:00 AM EDT - 3 months ago

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

Mar 28, 2026, 11:00 AM EDT - 3 months ago

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

EU regulator backs Sanofi's injectable version of blood cancer drug

Mar 27, 2026, 9:36 AM EDT - 3 months ago

EU regulator backs Sanofi's injectable version of blood cancer drug

Press release: Availability of the Q1 2026 aide-mémoire

Mar 24, 2026, 2:30 AM EDT - 4 months ago

Press release: Availability of the Q1 2026 aide-mémoire

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Mar 24, 2026, 2:00 AM EDT - 4 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

REGN

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Mar 23, 2026, 7:57 AM EDT - 4 months ago

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Sanofi launches innovation and operation centre in China

Mar 20, 2026, 10:58 AM EDT - 4 months ago

Sanofi launches innovation and operation centre in China

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 4 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mirecule Expands Strategic FSHD Collaboration with Sanofi

Mar 18, 2026, 7:00 AM EDT - 4 months ago

Mirecule Expands Strategic FSHD Collaboration with Sanofi

Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Mar 18, 2026, 2:00 AM EDT - 4 months ago

Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 4 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

ABBV AZN NVS

The Big 3: PR, ELF, SNY

Mar 17, 2026, 1:27 PM EDT - 4 months ago

The Big 3: PR, ELF, SNY

ELF PR

Sanofi: Information concerning the total number of voting rights and shares - February 2026

Mar 12, 2026, 1:30 PM EDT - 4 months ago

Sanofi: Information concerning the total number of voting rights and shares - February 2026

Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit

Mar 10, 2026, 4:16 PM EDT - 4 months ago

Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit

Dilly_Due
Dilly_Due Jul. 14 at 4:12 PM
$VXRT I don't agree that these votes sabotage anything as they don't have teeth yet. Plurality still applies right? But this vote could raise eyebrows in more important places such as the large activist investors, potential new suitors to fight an $SNY take under, who knows, maybe even a couple Attorneys General. Personally I hope 300 million votes are cast to WITHHOLD and it raises questions that only a share count would have determined. I don't know if that is possible but I would love it. Just my humble opinion. Do your own DD.
1 · Reply
MQuick
MQuick Jul. 14 at 2:08 PM
$GANX its time $SNY
0 · Reply
ZacksResearch
ZacksResearch Jul. 14 at 1:55 PM
💰 How $NVAX is quietly building a high-margin royalty business beyond COVID vaccines Novavax's proprietary Matrix-M adjuvant is gaining traction as more vaccine makers look to enhance immune responses without developing their own platform. Key developments: • $SNY received a license to use Matrix-M in additional vaccines, with Novavax eligible for up to $210M in milestones plus royalties • $PFE secured rights to Matrix-M in up to two disease areas under a deal worth up to $530M • Multiple partners are now evaluating Matrix-M across infectious disease and oncology programs • Future licensing deals could generate recurring revenue through upfront payments, milestones, royalties and supply agreements See the upside Wall Street expects for $NVAX. 👇 https://www.zacks.com/stock/research/NVAX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38772&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38772
1 · Reply
Makingmillions192
Makingmillions192 Jul. 14 at 1:51 PM
$MRK $SNY $VKTX While Big Pharma races to acquire oral GLP-1 delivery tech, this platform developer is about to drop human and next-gen animal datasets that could rewrite the market's tolerability standards. The Late-Summer Data Drop Schedule: Lexaria Bioscience ($LEXX) Mid-August 2026 | Animal Study #2 (GLP-1-A26-2) Pharma is watching platform compatibility and PK data for tomorrow's next-gen blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. Late August / Early September 2026 | Human Study #7 (GLP-1-H26-7) THE MAIN EVENT. Head-to-head 5-week steady-state human data comparing DehydraTECH-semaglutide tablets directly against Wegovy. Pharma is tracking bio-absorption and a projected ~40% reduction in GI side effects. Early September 2026 | Animal Study #1 (GLP-1-A26-1) Pharma is watching alternative novel formulations designed to bypass or improve upon traditional, erratic SNAC-inclusive carriers.
0 · Reply
grampslol
grampslol Jul. 13 at 4:24 PM
$MNKD furosemide drug won't be able to compete with furosemide products from $PFE $LLY $SNY amgen and countless other big pharma ... if approved furoscix will be afizzle part 2 ... lol #pumperslie #dilutionsthesolution
0 · Reply
Estimize
Estimize Jul. 13 at 10:09 AM
Wall St is expecting 1.10 EPS for $SNY Q2 [Reporting 07/30 BMO] http://www.estimize.com/intro/sny?chart=historical&metric_name=eps&utm_cont
0 · Reply
p3akyblinder
p3akyblinder Jul. 13 at 12:12 AM
$MLTX It’s very clear that the SLS crowd lacks biotech/investing literacy… hope it works out for them but they’re likely in for a rude awakening. $MRK $ABBV $LLY $SNY will all be MoonLake suitors soon imho GLTA
4 · Reply
Merlintrader
Merlintrader Jul. 12 at 10:57 PM
$SNY Sanofi, Guardant Health $GH and Pharvaris $PHVS - Biotech Radar July 13: catalysts, recent news and key risks https://www.merlintrader.com/biotech-radar-july13-2026/
0 · Reply
IM11
IM11 Jul. 10 at 7:21 PM
$GPCR corporate has been abnormally quiet the past 1 month. No Press Releases since the ADA, no management appearances that I am aware of. Seems like Sanofi's new CEO $SNY has also been pretty quiet other than hiring a new Medical Officer. Seem like maybe a buyout announcement between the two is coming? maybe Monday?
0 · Reply
SGL_FGHI
SGL_FGHI Jul. 10 at 3:18 PM
$TGTX $SNY $BMY $BIIB What’s beautiful about this for a forward-thinking Big Pharma is that TGTX can seamlessly be plugged into their existing neurology sales networks. The winning BP can immediately capture a $4B+ market cap potential without spending years scaling up a brand-new commercial pharmacy infrastructure. For example, because MG is treated by the exact same community neurologists who prescribe MS medications, a Big Pharma acquirer would need zero extra sales infrastructure to cross-sell Briumvi for this indication. The $140.00 per share threshold assumes competitive bidding. This is probably why the buyout will occur SUDDENLY. Personally, I doubt the winning BP will wait until the “de-risked” Phase 3 SUBQ results are reported (expected Q4 2026 / Q1 2027). I expect the winning proposal will be structured with upfront cash and CVR paid out if Briumvi successfully hits its phase 3 endpoint in Myasthenia Gravis OR Schizophrenia.
0 · Reply
SGL_FGHI
SGL_FGHI Jul. 10 at 2:47 PM
$TGTX There are just too many positives for the company's sales -- current and future: Briumvi IV, coming Briumvi SUBQ, and the Myasthenia Gravis (MG) and Schizophrenia (S) indications. This stock seems to only get better. What AI shows today for peak sales: $3.5B-$4.5B Briumvi IV; Briumvi SUBQ $5.25B-$7.0B; MG $750M-$1.2B; S $1.5B-$2.5B for the valuation model. This is a highly desirable multi-tiered autoimmune and neurology franchise. It should be quickly purchased by a Big Pharma with a crumbling patent portfolio, such as $SNY , $BMY , or $BIIB. According to AI, if Big Pharma enters a concurrent bidding war, the acquisition premium can easily breach the $140.00 per share threshold.
1 · Reply
Quantumup
Quantumup Jul. 9 at 3:28 PM
Oppenheimer🏁 $CNTB and said -- We are initiating coverage of Connect Biopharma (CNTB) with an Outperform rating and an $8 PT. $SNY - $REGN INSM VRNA INSM AZN GSK NVS AMGN UPB Oppenheimer added—Connect is developing rademikibart for inflammatory respiratory diseases. A single-asset story, CNTB is built on rademikibart (formerly CBP-201), a next-generation human IgG4 anti-IL-4Ra antibody that binds with higher affinity than dupilumab and, uniquely in the class, drives receptor-independent bronchodilation via pHSP20, producing FEV1 gains within 15 minutes through IV formulation. That speed could allow rademikibart to enter the acute exacerbation setting no current biologic is approved. FDA-aligned 28-day treatment-failure endpoint, which could then bridge patients into chronic maintenance where value concentrates. The two Phase 2 Seabreeze STAT studies (asthma and COPD, n = 160 each) read out in 2H26, the asthma topline in early September, as the valuation-inflection event.
0 · Reply
MQuick
MQuick Jul. 8 at 2:21 PM
$GANX now or never $SNY
1 · Reply
jlemx
jlemx Jul. 7 at 3:57 PM
$SGMO I don't think $SNY will let itself be taken for a ride by the $50 million deal between Sandy and Astellas for something worth $5 billion—and besides, the bankruptcy judge is no fool.
1 · Reply
jlemx
jlemx Jul. 6 at 6:47 PM
$SGMO Sanofi $SNY holds the monopoly on Fabry disease treatments and controls a global Fabry database, which collects data on all patients regardless of the therapy they are receiving. They generate $1 billion in annual sales and have a worldwide sales network for ERT. Do you really think they would just give up that business and let Astellas beat them to the punch? Even if they were to offer more than a billion for ST-920, it would be a smart move—not just defensively, but also to enhance their pipeline and boost revenue. I have high expectations for them, provided they play it smart.
1 · Reply
ANALYZING
ANALYZING Jul. 3 at 5:40 PM
$SNY why is this stock so undervalued? The debt to cash?
0 · Reply
clan
clan Jul. 2 at 4:35 PM
$MNKD $SPY For the good of all Mannkind! 🇺🇲💪🇺🇲 $NVO $SNY
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 2 at 11:22 AM
$TLSA buying more when the market opens $AXSM $CGTX and $SNY too 🧠 🧠 🧠 🧠
0 · Reply
moneybagged
moneybagged Jul. 1 at 8:57 PM
$OCUL $SNY
1 · Reply
IM11
IM11 Jul. 1 at 5:29 PM
$SNY I am hoping they announce a buyout of $GPCR between now and that July 30 Q2 report. But just a hunch, no strong evidence other than GPCR running up steadily the past month (potential leak?)
0 · Reply
Dilly_Due
Dilly_Due Jul. 1 at 3:28 PM
$VXRT What was the dip this morning? Did somebody make the mistake of putting a stop loss in low $.50's? Or did somebody think because sentinel results didn't come out in June that they should sell? Just an aside, curious if any limit orders in the mid $.50's filled for anyone this morning. "Market orders take priority" which I think means the "flash boys can drop the price, grab the stop at $.54 and not fill limit buys $.55-$.57. Anyone disagree? I'd love to hear that I'm wrong but I've been on that limit end watching my order get passed without filling. Nice bullish hammer forming! Who knows, maybe it turns into a "God Candle"? The President could create a black swan moment in the time it take to send out a Truth, right? I can dream can't I? This is one reason I like that the current suitor is $SNY . VXRT is a US company. Either way manufacturing will be in the US, but my guess is the current admin. might rather see a US BP get VXRT. Just my humble opinion. DO your own DD.
2 · Reply
MQuick
MQuick Jul. 1 at 12:34 PM
$GANX its time $SNY
0 · Reply